SHR-1316 Injection
Sponsors
Shanghai Hengrui Pharmaceutical Co., Ltd., Suzhou Suncadia Biopharmaceuticals Co., Ltd., Shanghai Shengdi Pharmaceutical Co., Ltd
Conditions
Advanced Cervical CancerAdvanced Solid TumorsMalignant Solid TumorsPD-L1-positive Locally Recurrent Unresectable or Metastatic Triple-negative Breast CancerSolid TumorWidespread Small Cell Lung Cancer
Phase 1
A Phase IB/II Clinical Study of SHR-9839 for Injection Combined With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors
RecruitingNCT06474455
Start: 2024-07-02End: 2029-12-01Target: 156Updated: 2026-05-11
Phase I Clinical Study of SHR-1316 (SC) Combined With Carboplatin and Etoposide as First-line Treatment for Extensive Stage Small Cell Lung Cancer
RecruitingNCT07009457
Start: 2025-06-16End: 2028-09-30Target: 48Updated: 2025-07-04
A Study of SHR-7367 With Anti-tumor Agents in Patients With Solid Tumors
RecruitingNCT07229586
Start: 2025-12-02End: 2027-12-31Target: 100Updated: 2025-12-19
Phase 2
Phase 3
A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer
RecruitingNCT07111832
Start: 2025-08-20End: 2028-12-31Target: 400Updated: 2025-12-18
A Phase III Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy Versus Placebo Combined With Concurrent Chemoradiotherapy for the Treatment of Locally Advanced Cervical Cancer
RecruitingNCT07168200
Start: 2025-10-17End: 2028-12-01Target: 720Updated: 2026-04-15